Spirometry is an examination that measures the function of our lungs, particularly the patency of the respiratory tract.

Everyone should have this examination done at least once in their life.

Not only is it performed to diagnose, monitor and determine the progression of bronchial asthma, but it also examines the bronchial airflow (the flow rate) as well as the volumes and capacities of the lung's air spaces. The examination is performed by means of a device known as spirometer.

During the examination, the patient stands or sits in an upright position, holding a mouthpiece tightly in the mouth. A nose clip is applied to prevent nose breathing.

The examination is not particularly bothersome for the patient, who breathes in and out through the mouthpiece and performs the instructions of the attending physician. The mouthpiece held in the patient’s mouth is connected to the spirometer by means of a tube (a flexible plastic pipe like the one used in vacuum cleaners but with a smaller diameter). There are different procedures for the examination. However, it mostly measures the vital capacity and its components, and registers the forced expiration. Spirometry helps to determine a number of parameters, the most important being: FEV1, FVC, PEF and the FEV1/FVC ratio (known as the Tiffeneau index). The normal values of these indices are specified on the basis of population tests and depend on: sex, age, height and race.

Forced expiratory volume in 1 second (FEV1):

The parameter refers to the amount of air exhaled from the lungs within the first second of forced exhalation. It shows the degree of airway obstruction, or the narrowing of bronchial passages. Obstruction occurs in bronchial asthma and COPD, and may be caused by bronchospasm, swelling of the bronchial mucosa or bronchial lining by mucosal secretion. Pulmonary obstruction can be mild (>70% of the predicted value), moderate (60-69%), moderate-severe (50-59%), severe (35-49%) and very severe (<35%)

Forced vital capacity (FVC):

It refers to the total amount of air exhaled from the lungs after a maximum inhalation. It shows the magnitude of restrictions, or conditions that limit expansion and contraction of the lungs in the course of various diseases and pathologies restraining chest mobility. Tiffaneau index: The index is calculated from multiplication of the absolute values of FEV1 and FVC (FEV1/FVC). Values below < 0.7 indicate obstruction of the bronchial tree.

Peak expiratory flow (PEF):

This parameter can be measured by means of a special simple device known as a peak flow meter. Similarly to the FEV1 index, it determines the degree of bronchial obstruction. Because the procedure can be performed using a cheap and simple apparatus, it can be carried out by the patient at home (which is recommended). The measurement is easy to carry out: After resetting the scale on the device, the patient makes a maximum exhalation which is followed by a maximum inhalation. Next, without holding breath, the patient exhales through the mouthpiece of the device. The indicator of the apparatus shows the flow value. The use of a peak flow meter is a good method of monitoring the course of bronchial asthma in a domestic environment by the patient (for more information see the ‘patient guide’ tab).

Bronchial obstruction reversibility test:

This test is performed in order to assess the reversibility degree of the patient’s bronchial obstruction. It is prescribed for patients with the FEV1 index below normal range. It involves administration of a specific dose of a bronchodilating agent to the patient and repetition of the spirometry examination after 15 minutes. Next, assessment is done on the extent to which the FEV1 indicator has improved (increased in value).


Centrum Zdrowej Skóry The Healthy Skin Centre ul. Racławicka 27 02-601 Warsaw Centrum Medyczne Damiana Polskie Towarzystwo Lekarzy Medycyny Estetycznej POLME

Contact form

Data processing agreement template – for the purposes of marketing products and own services *

Marketing contact agreement template

Electronic messages (e-mail, SMS/MMS, online platforms, including social networking sites , push notifications) *

Voice calls (phone calls, IVR voice messages) *

Data processing agreement template – for the purposes of marketing Medicover Polska’s products and services

* required fields

Basic information on processing personal data for marketing purposes
  • Data controller: Centrum Medyczne Damiana Holding Sp. z o.o., Wałbrzyska 46,00-739 Warszawa
  • Purposes of processing: marketing own products and services [incl. profiling]; marketing Medicover Polska‘s products and services** [including profiling]
  • Legal basis for processing: Your consent
  • Rights related to data processing: right to withdraw consent for processing personal data; right to access personal data; other rights referred to in the detailed information on processing data
  • Data recipients : Entities processing personal data on behalf of Centrum Medyczne Damiana Holding Sp. z o.o.

For detailed information on processing, see INFORMATION CLAUSE FOR CENTRUM MEDYCZNE DAMIANA HOLDING SP. Z O.O.

** Medicover Sp. z o.o., Al. Jerozolimskie 96, 00-807 Warszawa, Medicover Forsakrings AB (Publ.) Spółka Akcyjna-Oddział w Polsce, Al. Jerozolimskie 96, 00-807 Warszawa, Medi Partner Sp. z o.o., Cybernetyki 19, 02-677 Warszawa, Medvit Sp. z o.o., Puławska 42b, 05-500 Piaseczno, INACTIVE_Centrum Medycyny Pracy Zakład Leczniczo-Profilaktyczny, Lotnicza 1, 82-500 Kwidzyn, Denta Care Sp. z o.o., Al. Jerozolimskie 96, 00-807 Warszawa, PROPSYCHE A. i B. Ziołkowscy Sp. Jawna, Pawia 4/2, 00-164 Warszawa, Centrum Medyczne Damiana Holding Sp. z o.o., ul. Wałbrzyska 46, 02-739 Warszawa, Care Experts Sp. z o.o., Al. Jerozolimskie 96, 00-807 Warszawa, INVIMED-T Sp. z o.o., ul. Rakowiecka 36, 02-532 Warszawa, Medicover Benefits Sp. z o.o. (od 09.01.2017), Al. Jerozolimskie 96, 00-807 Warszawa, Rehasport Clinic Sp. z o.o. (od 09.01.2017), ul. Górecka 30, 60-201 Poznań.

Copyright © Healthy Skin Centre 2008-2018
Proszę czekać Proszę czekać...